You are viewing: Australia Leukapheresis Market analysis
Part of: Leukapheresis Market (Global)

The Australia Leukapheresis Market was valued at $1.72 Million in 2026 and projected to reach to $2.74 Million by 2031, representing a compound annual growth rate of CAGR 9.7%. Australia's leukapheresis market is poised for sustained growth through 2031, driven by increasing prevalence of hematologic malignancies and growing adoption of CAR-T cell therapies across major Australian medical centers.

Australia Leukapheresis Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Australia Leukapheresis Market Trends and Insights

  • This represents a compound annual growth rate (CAGR) of 9.7%, outpacing global averages and reflecting strong demand for advanced cell separation technologies in Australia's healthcare sector.
  • Australia's investment in oncology and immunotherapy treatments is driving adoption of leukapheresis procedures, as these technologies are critical for CAR-T cell therapy and other cellular immunotherapies. The Australian market benefits from a well-developed healthcare infrastructure, increasing prevalence of hematologic malignancies, and growing clinical awareness among healthcare providers.
  • Australia's regulatory environment and reimbursement landscape support the adoption of leukapheresis equipment and services.
  • Between 2026 and 2031, Australia is expected to see accelerated market penetration as more treatment centers establish leukapheresis capabilities to meet rising patient demand for advanced cellular therapies..

Key Market Statistics

  • CAGR (2026-2031) CAGR 9.7%
  • Market Size, 2026 ~USD 1.72 Million
  • Forecast, 2031 ~USD 2.74 Million
  • Country Australia

Australia Leukapheresis Market Overview

Strong Growth Trajectory :

Australia's leukapheresis market is expanding at 9.7% CAGR, significantly outpacing the global average of 8.9%, driven by increasing adoption of advanced cell separation technologies in Australian healthcare facilities.

Market Valuation Growth :

The Australian market is projected to grow from $1.72 million in 2026 to $2.74 million by 2031, representing a 59% increase over the five-year forecast period, indicating strong investment in oncology and immunotherapy infrastructure.

Oncology Investment Focus :

Australia's healthcare sector is increasingly investing in advanced oncology and immunotherapy treatments, creating substantial demand for leukapheresis procedures and supporting equipment in major medical centers and specialized treatment facilities.

Healthcare Technology Adoption :

Australian hospitals and treatment centers are rapidly adopting cutting-edge cell separation technologies, reflecting the country's commitment to providing world-class cancer care and positioning itself as a leader in cellular therapy innovation.

Australia Leukapheresis Market Dynamics

  • The market's 9.7% CAGR reflects strong healthcare infrastructure investment and rising demand for advanced cell separation technologies in oncology departments. Key growth drivers include expanding immunotherapy programs, increased government healthcare funding, and growing patient awareness of advanced treatment options.
  • Australian healthcare providers are prioritizing cellular therapy capabilities, positioning the country as a regional hub for advanced cancer treatment.
  • This momentum is expected to continue as more facilities establish leukapheresis capabilities and treatment protocols expand..

Related Ecosystem

Key Takeaways

  • Australia's leukapheresis market is valued at $1.72 million in 2026 and is forecast to reach $2.74 million by 2031, representing a 9.7% CAGR.
  • Australia's market growth outpaces the global average of 8.9% CAGR, driven by strong healthcare infrastructure and increasing adoption of CAR-T therapies.
  • Australia's regulatory framework and reimbursement policies support leukapheresis technology adoption across major treatment centers.
  • Rising prevalence of hematologic malignancies and immunotherapy demand are key growth catalysts for Australia's leukapheresis market through 2031.

Leukapheresis Market Report Scope

Report Metric Details
Base Year 2026
Fastest Growing Segment MULTIPLE MYELOMA (Indication)
Forecast Period 2026–2031
Growth Rate CAGR of 8.9% from 2026 to 2031
Largest Segment ACUTE LYMPHOCYTIC LEUKEMIA (Indication)
Market Size Base Year (Billions) ~USD 0.09 (2026)
Revenue Forecast (Billions) ~USD 0.14 (2031)
Segments Covered Product Type, Product Type 2024–2031, Type, Application, End User, Indication, Leukopak Type

Australia Leukapheresis Market Report Segmentation

7 segment dimensions are covered across the global market.

By Product Type

  • Devices
  • Disposables
  • Leukapheresis Devices
  • Leukapheresis Disposables

By Product Type 2024–2031

  • Collection Kits & Accessories
  • Filters & Membrane Consumables
  • Tubing Sets & Collection Bag

By Type

  • Australia
  • Belgium
  • Brazil
  • Canada
  • Centrifugal Devices
  • China
  • Diseased Leukopaks
  • France
  • Germany
  • India
  • Isolated Pbmcs
  • Italy
  • Japan
  • Kingdom Of Saudi Arabia (Ksa)
  • Membrane Separators
  • Mexico
  • Mobilized Leukopaks
  • Netherlands
  • New Zealand
  • Non-Mobilized Leukopaks
  • Poland
  • Rest Of Asia Pacific
  • Rest Of Europe
  • Rest Of GCC Countries
  • Rest Of Latin America
  • Rest Of Middle East & Africa
  • South Korea
  • Spain
  • Switzerland
  • Thailand
  • UK
  • United Arab Emirates (UAE)
  • US

By Application

  • Research Applications
  • Therapeutic Applications

By End User

  • Academic & Research Institutes
  • Blood Component Providers & Blood Centers
  • Contract Research Organizations
  • Hospitals & Transfusion Centers
  • Pharmaceutical & Biotechnology Companies

By Indication

  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Hepatocellular Carcinoma
  • Multiple Myeloma
  • Non-Hodgkin’S Lymphoma
  • Other Indications
  • Pancreatic Cancer

By Leukopak Type

  • Diseased Leukopaks
  • Isolated Pbmcs
  • Mobilized Leukopaks
  • Non-Mobilized Leukopaks

AUSTRALIA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031

Segment20242025202620272028202920302031CAGR (%)
ACADEMIC & RESEARCH INSTITUTES0.250.270.30.330.360.390.430.479.3
BLOOD COMPONENT PROVIDERS & BLOOD CENTERS0.9111.111.221.361.51.671.8510.8
HOSPITALS & TRANSFUSION CENTERS0.460.510.560.610.680.740.820.9110.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES0.150.170.180.190.210.230.250.278.1
TOTAL1.781.952.152.362.62.863.163.4910.2

AUSTRALIA: LEUKOPAKS MARKET, BY END USER, 2024–2031

Segment20242025202620272028202920302031CAGR (%)
ACADEMIC & RESEARCH INSTITUTES3.74.124.595.135.746.447.248.1612.2
CONTRACT RESEARCH ORGANIZATIONS0.330.360.390.420.460.510.560.629.7
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES1.281.451.641.862.112.412.753.1413.9
TOTAL5.315.926.627.418.329.3610.5511.9212.5

Target Audience

  • Medical Device Manufacturers : Manufacturers of leukapheresis equipment and cell separation technologies need Australia-specific market data to assess market opportunity, plan product launches, and develop localized commercial strategies for this high-growth region.
  • Healthcare Facility Operators : Australian hospitals, cancer centers, and specialized treatment facilities require market insights to justify capital investments in leukapheresis technology, benchmark against peers, and plan cellular therapy program expansion.
  • Pharmaceutical and Biotech Companies : Companies developing CAR-T therapies and immunotherapies need Australia market intelligence to understand treatment adoption rates, identify clinical trial sites, and plan commercial launch strategies for cellular therapies.
  • Healthcare Investors and Consultants : Investment firms and management consultants analyzing Australian healthcare opportunities require detailed market data to evaluate investment potential, assess competitive positioning, and identify growth drivers in the leukapheresis sector.
  • Healthcare Policy and Government Bodies : Australian health authorities and policy makers need market research to inform healthcare infrastructure planning, funding allocation decisions, and regulatory frameworks supporting advanced cellular therapy adoption.

Key Companies in the Australia Leukapheresis Market

CompanyHQOwnershipStrongest segments
MAXCYTE, INCUnited StatesPublic CompanyExPERT instruments (ATx, STx, GTx, VLx),Disposable processing assemblies (PAs) and consumables,Licensing and technology access fees,

MAXCYTE, INC

MaxCyte, Inc. is a United States-based biotechnology company founded in 1998 that specializes in cell engineering technologies. As a publicly traded company, MaxCyte operates with 91 employees and develops innovative solutions for cell-based therapies and research applications.

Reasons to Buy this Report

  • Market-Specific Growth Data : Access detailed Australia-focused market sizing and forecasts with 9.7% CAGR projections through 2031, enabling accurate business planning and investment decisions specific to the Australian healthcare landscape.
  • Competitive Landscape Intelligence : Understand the competitive dynamics within Australia's leukapheresis market, including key players, market share distribution, and strategic positioning of suppliers in this high-growth regional market.
  • Healthcare Infrastructure Insights : Gain comprehensive understanding of Australia's oncology and immunotherapy infrastructure, facility adoption rates, and technology deployment patterns to identify market entry and expansion opportunities.
  • Regulatory and Reimbursement Analysis : Obtain Australia-specific regulatory requirements, reimbursement pathways, and healthcare policy frameworks that directly impact leukapheresis market dynamics and commercial viability.
  • Strategic Market Positioning : Leverage Australia-specific market intelligence to develop targeted go-to-market strategies, identify high-potential customer segments, and optimize resource allocation for maximum market penetration.

Frequently asked questions

What is the current size of Australia's leukapheresis market?

Australia's leukapheresis market was valued at $1.72 million in 2026 and is expected to grow to $2.74 million by 2031.

What is the projected growth rate for Australia's leukapheresis market?

Australia's leukapheresis market is projected to grow at a CAGR of 9.7% from 2026 to 2031, outpacing the global average.

What factors are driving growth in Australia's leukapheresis market?

Key drivers include increasing adoption of CAR-T cell therapies, rising prevalence of hematologic malignancies, strong healthcare infrastructure, and supportive regulatory policies in Australia.

How does Australia's leukapheresis market compare to global trends?

Australia's market is growing faster than the global average, with a 9.7% CAGR compared to the global 8.9% CAGR, reflecting strong regional demand and healthcare investment.

Which treatment centers in Australia are adopting leukapheresis technology?

Major oncology and hematology centers across Australia are increasingly establishing leukapheresis capabilities to support advanced cellular immunotherapy programs.

RESEARCH METHODOLOGY

This study extensively used both primary and secondary sources. The research involved studying various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the leukapheresis market. It was also used to identify key players in the market and classify and segment the industry based on trends to the most detailed level. Additionally, significant developments related to market and technology perspectives were noted. A database of the primary industry leaders was also created using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the leukapheresis market. Primary sources from the demand side include healthcare professionals from blood component providers & blood centers, academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & transfusion centers.

A breakdown of the primary respondents is provided below:

BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS, BY COMPANY TYPE, DESIGNATION, AND REGION

Leukapheresis Market
Size, and Share

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.

Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the leukapheresis market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

Leukapheresis Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition

Leukapheresis is the process of separating white blood cells from the whole blood. Therapeutic leukapheresis procedures are used to treat hyperleukocytic leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin’s lymphoma.

Leukopaks are enriched leukapheresis products that contain mononuclear leukocytes (lymphocytes and monocytes) and are used to develop cell-based therapeutics

Key Stakeholders

  • Apheresis device manufacturers and distributors
  • Leukapheresis product manufacturers and distributors
  • Leukopak manufacturers and distributors
  • Pharmaceutical and biotechnology companies
  • Healthcare service providers (including hospitals and transfusion centers)
  • Cancer treatment centers
  • Blood component providers & blood centers
  • Contract research organizations (CROS)
  • Academic and research institutes
  • Government associations
  • Market research and consulting firms
  • Venture capitalists and investors

Report Objectives

  • To define, describe, segment, and forecast the leukapheresis market by type, application, end user, and region, and the leukopaks market, by type, indication, end user, and region
  • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall leukapheresis market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the leukapheresis market in five main regions (along with their respective key countries), namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the leukapheresis market and comprehensively analyze their core competencies and market share
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships

Available customizations:

With the given market data, MarketsandMarkets offers customizations to meet your company’s specific needs. The following customization options are available for the report:
  • Company Information

Detailed analysis and profiling of additional market players (up to 5)

  • Geographic Analysis

Further breakdown of the Rest of Europe leukapheresis market into Austria, Finland, and other countries

Further breakdown of the Rest of Latin America leukapheresis market into Colombia, Chile, and other countries

  • Competitive Landscape Assessment

Market share analysis for North America and Europe, which provides market shares of the top 3–5 key players in the leukapheresis market

Competitive leadership mapping for established players in the US

 

Get the Full Leukapheresis Market Report

Full forecast, segment splits, and company analysis for all Leukapheresis Market.

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
DMCA.com Protection Status